Cerity Partners
HAE icon

Cerity Partners’s Haemonetics HAE Stock Holding History

Cerity Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62M Sell
34,903
-4,936
-12% -$317K ﹤0.01% 1443
2026
Q1 		$2.25M Buy
39,839
+4,991
+14% +$325K ﹤0.01% 1424
2025
Q4 		$2.79M Buy
34,848
+15,877
+84% +$1.07M ﹤0.01% 1223
2025
Q3 		$925K Buy
18,971
+4,952
+35% +$307K ﹤0.01% 1633
2025
Q2 		$1.05M Buy
14,019
+2,961
+27% +$196K ﹤0.01% 1499
2025
Q1 		$703K Buy
11,058
+2,713
+33% +$185K ﹤0.01% 1586
2024
Q4 		$671K Sell
8,345
-510
-6% -$41K ﹤0.01% 1604
2024
Q3 		$712K Buy
8,855
+2,102
+31% +$170K ﹤0.01% 1581
2024
Q2 		$559K Sell
6,753
-2,109
-24% -$186K ﹤0.01% 1496
2024
Q1 		$756K Buy
+8,862
New +$695K ﹤0.01% 1408

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Cerity Partners's HAE Position: Q2 2026 in Review

Cerity Partners reduced its Haemonetics (HAE) stake by 12% in Q2 2026, selling an estimated $317K and leaving 34,903 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

Cerity Partners first reported a position in HAE in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.79M in Q4 2025. 316 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Cerity Partners held 34,903 shares of Haemonetics worth $2.62M as of Q2 2026.
  • Cerity Partners sold 4,936 Haemonetics shares in Q2 2026, an estimated $317K.
  • Haemonetics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1443 holding.
  • Cerity Partners first reported a position in Haemonetics in Q1 2024 and has held it in 10 quarters since.
  • Cerity Partners's Haemonetics position peaked at $2.79M in Q4 2025.
  • 316 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.